A Cerebellar High-Grade Neuroepithelial Tumour with BCOR Alteration in a five-year-old Child: A case report. by Al-Battashi, Abeer et al.
UCSF
UC San Francisco Previously Published Works
Title
A Cerebellar High-Grade Neuroepithelial Tumour with BCOR Alteration in a five-year-old 
Child: A case report.
Permalink
https://escholarship.org/uc/item/9989k0q0
Journal
Sultan Qaboos University medical journal, 19(2)
ISSN
2075-051X
Authors
Al-Battashi, Abeer
Al Hajri, Zahra
Perry, Arie
et al.
Publication Date
2019-05-01
DOI
10.18295/squmj.2019.19.02.012
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
1National Oncology Centre, Royal Hospital, Muscat, Oman; 2Department of Pathology, Khoula Hospital, Muscat, Oman; 3Department of Pathology, University 
of California, San Francisco, United States; 4Department of Education & Training, Royal Hospital, Muscat, Oman
*Corresponding Author’s e-mail: abeer_albattashi@hotmail.com
ينج يريغت عم ةيلاع ةجرد وذ بيصع يراهظ يخيمخ مرو 
تاونس سخم هرمع لفط دنع BCOR
ةلاح ريرقت
يثيغلا ميهاربإا ،ةيدنكلا ةنينح ،ييرب يرآا ،ةيرجلحا ةرهز ،ةيش�اطبلا يربع
abstract: New groups of high-grade neuroepithelial tumours (HGNET) have emerged from the reclassification 
of central nervous system (CNS) embryonal tumours that have recognised CNS HGNET with BCOR alteration 
(CNS HGNET-BCOR). We report a two-year, nine-month-old Omani boy who presented to the Royal Hospital, 
Muscat, Oman, in 2015 with subacute head tilting and neck pain. A well-defined cerebellar lesion was found and he 
was treated with standard chemoradiotherapy. After a relapse at the age of five years, molecular testing revealed a 
BCOR alteration. He was treated with further surgery and high-dose chemotherapy; unfortunately, he relapsed and 
died three years after he was diagnosed.
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 زاهجلل ةينيلجا ماروألاا فينش�ت ةداعإا للاخ نم )HGNET( ةجردلا ةيلاع ةيبش�علا ةيراهظلا ماروألاا نم ةديدج تاعوممج ترهظ :ص�خللما
 .هتاذب مئاق نايكك BCOR-HGNET CNS ـب هل زمريو BCOR ينج في لوتح عم HGNET CNS لمش�تو )CNS( يزكرلما يبش�علا
 مرو هنأا ىلع اًقباش� هش�يخش�ت تم يذلاو ،BCOR-HGNET CNS ـب باش�م )رهش�أا ةعش�تو ينماع هرمع( نيامع لفط لوا ةلاح انه س�رعتش�ن
 يئايميكلا جلاعلاب جلوعو لماعلما ةحش�او ةيخيمخ ةفآاب 2015 ماع في نامع ،طقش�م ،نياطلش�لا ىفش�تش�لما لىإا س�يرلما اذه مدق .يقبد يمورأا
 ةيحارج ةيلمعب هجلاع تمو BCOR ينج في يرغت نع ةيئيزلجا تارابتخلاا تفش�ك ،تاونش� س�ملخا رمع في س�يرلما ةش�اكتنا دعبو .يعاعش�لااو
.هتلاح س�يخش�ت نم تاونش� ثلاث دعب فيوتو ىرخا ةرم س�يرلما س�كتنا ،ظلحا ءوش�ل .يئايميكلا جلاعلا نم ةيلاع ةعرجو ىرخا
.نامع ؛ةلاح ريرقت ؛ةينينج ماروأا ؛يشر�بلا BCOR ينتورب ؛يقبد يمورأا مرو ؛يبش�ع يراهظ مرو :ةيحاتفلما تاملكلا
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system primitive neuroectodermal tumours (PNETs) 
using a DNA methylation technique and transcriptomic 
profiling.1 Very few cases have been described in the 
literature within this unique genetic landscape.1,3,4 This 
report describes the first Omani patient with BCOR 
alteration in a CNS high-grade neuroepithelial tumour 
(HGNET). 
Case Report
A two-year, nine-month-old boy presented in 2015 
to the Royal Hospital, Muscat, Oman, with subacute 
head tilting and neck pain. In addition, he had a mild 
headache but no vomiting or altered sensorium. There 
was no significant personal or family history of tumours 
or malignancies. Clinically, he had a left side trochlear 
nerve palsy, resulting from high intracranial pressure 
and brainstem compression on the trochlear nucleus 
with no other focal neurological signs and no cerebellar 
signs. A magnetic resonance imaging (MRI) scan rev- 
Managing children with central nervous system (CNS) tumours is challenging as most data have been extrapolated from 
adult studies.1 Therefore, different diagnostic and thera- 
peutic modalities have been implemented to tackle 
this challenge. Molecular testing using next-generation 
genome sequencing (NGS) has aided researchers in 
understanding the different behaviours and outcomes 
of tumours that are grouped by histopathology. In 2016, 
the World Health Organization (WHO) reclassified 
certain brain tumours according to their biology, for 
example, medulloblastoma and ependymoma.2 Further 
reclassification is being studied for other categories as 
tumours can be biologically distinct from each other, 
which delineates unique and separate tumour entities. 
This might aid in tailoring new treatment approaches 
to improve the survival of children affected by such 
tumours.
In 2016, Strum et al. described new brain tumour 
entities by reclassifying a group of central nervous 
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ealed a right-sided cerebellar mass (5.5 × 5.6 cm). It was 
well-defined, predominantly solid with some cystic 
components, hyperintense in T2 and hypointense in 
T1 with a mild diffusion restriction [Figures 1A and B]. 
The mass caused compression of the fourth ventricle 
with resultant hydrocephalus and a degree of tonsillar 
herniation. Magnetic resonance spectroscopy (MRS) 
showed a reduction in N-acetylaspartate and a high 
choline peak with a lactate/lipid doublet that was 
indicative of a very aggressive tumour [Figure 1C]. 
There was no evidence of metastasis in the cerebral 
hemispheres, the spine or cerebrospinal fluid. These 
findings could be due to many aggressive infratentorial 
lesions, such as anaplastic ependymoma, high grade 
glioma, medulloblastoma and atypical teratoid rhabdoid 
tumour. 
The patient underwent a gross total excision within 
a few days of his presentation using an occipital 
craniotomy approach. Intra-operatively, the tumour was 
very vascular. No residual tumour tissue was observed 
on the post-operative MRI scan. Pathology showed a 
well-circumscribed, highly cellular neoplasm composed 
of moderately pleomorphic cells with irregular nuclei 
and vesicular chromatin, arranged mostly in sheet-like 
to fascicular architectural patterns [Figure 2A]. In many 
areas, the tumour cells formed perivascular collections 
suggestive of pseudorosettes. Palisading necrosis and 
collections of apoptotic nuclei (apoptotic lakes) were also 
present and mitoses were abundant [Figures 2B and C]. 
Microvascular proliferation was not identified. Immuno- 
histochemistry showed negative stains for glial fibrillary 
acidic protein, synaptophysin, and oligodendrocyte tran- 
scription factor 2. The neuronal nuclei were focally 
positive for epithelial membrane antigen testing which 
demonstrated occasional cytoplasmic to paranuclear 
dot-like staining and the neurofilament protein staining 
had patchy positivity [Figure 3]. The tumour retained 
INI1 in the nuclei.
The patient was stable post-operatively and was 
started on bridging systemic chemotherapy, as he was 
less than three years of age at the time. The chemo- 
therapy consisted of four cycles of vincristine, cyclo- 
phosphamide, cisplatin and etoposide. He was then ini- 
tiated on chemoradiotherapy, during which he received 
focal radiotherapy in the form of intensity modulated 
radiotherapy at a total dose of 54 Gy in 30 fractions 
with concurrent temozolamide at a dose of 75 mg/m2. 
He was then started on maintenance temozolamide at 
a dose of 200 mg/m2; one year after presentation, he 
completed the twelve cycles uneventfully.
His post-radiotherapy MRI scan and his follow-
up scans showed that he was in remission with no 
residual tumour tissue or recurrence. In 2017, at the 
age of five years and two months—exactly one year 
after the completion of treatment—a surveillance scan 
detected a local recurrence in the primary tumour 
bed in the right cerebellum (Figures 2B and 4A). He 
underwent another gross total excision of the tumour 
with post-operative scans showing no residual tumour 
 
Figure 1: Magnetic resonance imaging scans of the head of 
a five-year-old boy showing a cerebellar primary tumour 
that is (A) hypointense on T1 and (B) hyperintense on 
T2 with both solid and cystic components. Magnetic 
resonance spectroscopy showed (C) a choline peak with 
low N-acetylaspartate and a lactate/lipid doublet. 
 
Figure 2: Haematoxylin and eosin stains (A) at x20 showing 
a highly cellular neoplasm (arrow) (B) at x100 magnification 
showing tumour cells arranged in a spongioblastic pattern 
and palisading necrosis with apoptotic lakes (arrows) and (C) 
at x400 magnification showing numerous mitotic figures. 
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tissue. The histological features of the specimen were 
identical those of the specimen examined in 2015.
Next-generation sequencing (NGS) of the tumour 
was done using the University of California, San 
Francisco 500 Next-Generation Sequencing Cancer 
Gene Test that has the ability to analyse 479 cancer 
genes. It uses capture-based NGS by analysing genomic 
DNA from both tumour as well as normal cells. Target 
enrichment was performed by hybrid capture using 
custom oligonucleotides. It demonstrated an internal 
tandem duplication within exon 15 of the BCOR gene 
(this begins at codon p.V17141, which is an insertion 
of 30 amino acids). Additional alterations were 
telomerase reverse transcriptase (TERT) amplification 
and SMARCA2 mutation. Other alterations, such as 
IDH1, IDH2, Histone 3, MYCN, or PDGFRA were not 
demonstrated. The TERT and SMARCA2 alterations 
have not been previously reported within the CNS-
HGNET-BCOR entity. 
The patient was restarted on temozolamide with 
the addition of bevacizumab (an antiangiogenic agent 
which inhibits the vascular endothelial growth factor). 
He received a total of six courses and remained well. 
Subsequently, he received four tandem autologous bone 
marrow transplants at the age of five years, six months 
based on the paediatric CNS embryonal tumour protocol. 
He presented with an extensive local relapse two months 
after transplantation. He developed severe obstructive 
hydrocephalus and reduced level of consciousness and 
was treated palliatively. He died three years after his 
initial presentation.
Verbal consent was obtained from the patient’s 
parents for the publication of this case report.
Discussion
A cluster of CNS PNETs, also known as embryonal 
tumours were regrouped into the following four molec- 
ular sub-categories by Strum et al. in 2016: CNS neuro- 
blastoma with FOXR2 activation, CNS Ewing sarcoma 
family tumour with CIC alteration, CNS high-grade 
neuroepithelial tumour with MN1 alteration and CNS 
HGNET-BCOR.1 There are very few reports of CNS-
HGNET-BCOR in the literature. This patient exhibited 
a common location for these tumours, which is within 
the cerebellum. However, these tumours can arise any- 
where within the supratentorium or posterior fossa.1,3,4 
This tumour has been rarely described as disseminating 
beyond the neuroaxis. There have been cases that 
described bone metastasis and subcutaneous nodule 
seeding.3,4
HGNET-BCOR was described after reviewing a 
variety of tumours, including medulloblastoma, epen- 
dymoma and high-grade glioma.1 Despite the different 
initial histological diagnosis, these tumours share pathol- 
ogical features including proliferation of uniform round 
or ovoid cells with fine chromatin and a rich arborising 
capillary network. Other characteristics may include 
stellate-, vacuolated- or spindle cell-cytomorphology, 
myxoid stromal changes and perivascular pseudoro- 
settes.3
Radiologically, HGNET-BCOR share features with 
other high-grade lesions including increased enhance- 
ment and diffusion restriction, as seen in the current 
patient. They can be solid, cystic or both and have 
features of a highly malignant lesion on MRS [Figure 1C]. 
The current patient had similar features to other patients 
described in the literature, with the mass being well-
demarcated, hypointense on T1 and hyperintense on 
T2 [Figures 1A & B and 4A & B).1,2 The signal intensity 
in the present patient was fairly homogenous with a 
significant cystic component. 
 
Figure 3: Immunohistochemistry of the tumour cells of a 
five-year-old boy. (A) Epithelial membrane antigen staining 
showing cytoplasmic to paranuclear dot-like staining and 
(B) sporadically positive neurofilament. 
 
Figure 4: Magnetic resonance imaging scans of the head 
of a five-year-old boy showing the tumour at recurrence 
in the same primary site (arrows) with the same features as 
the primary tumour, as there is a well-circumscribed lesion 
that is (A) hypointense on T1 and (B) hyperintense on T2. 
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Different treatments have been attempted for 
HGNET-BCOR. These included the use of multi-agents 
(cisplatin, etoposide and cyclophosphamide), bevaci- 
zumab, the use of intrathecal chemotherapy (metho- 
trexate and topotecan) and autologous stem cell trans- 
plants.4 Yoshida et al. reported two patients who 
received autologous stem cell transplants and were 
both alive at the time of publication.4 In terms of local 
control, a total surgical excision is highly recommended 
and most patients received either focal radiotherapy or 
craniospinal radiotherapy with the majority receiving 
the former.3,4 In general, this tumour has a poor 
outcome and a tendency for relapse.3,4
Conclusion
The diagnostic approach to CNS tumours is evolving 
into sophisticated molecular profiling, which aids 
researchers in understanding the differences in 
behaviour between tumours that fall into the same 
histological classification and, therefore, their prog- 
nosis and different therapeutic approaches. The new 
WHO classification might reclassify these new entities 
into different categories. As the number of CNS 
HGNET-BCOR cases is very limited in the literature, 
more pathological, clinical and biological testing is 
required to understand this new entity.
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